Raptor Falls on Positive Data in Nephropathic Cystinosis
By Jennifer Boggs
Tuesday, July 26, 2011
Raptor Pharmaceuticals Corp.'s RP103, a delayed-release version of cysteamine, hit its primary endpoint in a Phase III study in nephropathic cystinosis, putting the firm in a good position for filing a new drug application (NDA) in the ultra-orphan indication, though that success was not exactly mirrored in the company's stock.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.